SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS)
$0 None (None%)
Analysed SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) News Sources
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
05-11-2025
yahoo.com
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
19-06-2025
yahoo.com
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
01-05-2025
yahoo.com
What is the current price of SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS)?
The current price of SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) is $0.
SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) since the previous trading day is $None.
SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS)?
The most recent average sentiment score for SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) is 72 out of 100.
What is the most recent average sentiment for SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS)?
The most recent sentiment for SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS) is .
SEC-8K** Filing Available For SHIN NIPPON BIOMEDICAL LABOR (SBLOF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.